Jacobsmeyer Barbara Ann
Known title: President & CEO, HHHCIK: 0001691132
Associated companies
Transaction History
| EHC | ▲ Buy | Grant | 5,897 | $0 | 2/25/2022 | View on chart |
| EHC | ▲ Buy | Grant | 9,875 | $0 | 2/25/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 584 | $38K | 2/24/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 1,048 | $69K | 2/22/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 3,455 | $225K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.